A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2004
11/25/2004	US20040234555 Using 5-aminolevulinic acid
11/25/2004	US20040234544 Formulation containing (lyso-)phosphatidylserine for the prevention and treatment of stress states in warm blooded animals
11/25/2004	US20040234536 Polypeptide containing antigen segment; mixture with antibodies; immunostimulants
11/25/2004	US20040234526 Use of a compound antagonist of esm-1 protein for producing a medicine for treating cancer
11/25/2004	US20040234522 therapy, diagnosis of immunology diseases; response to antigenic stimulants; cell differentiation of lymphocytes
11/25/2004	US20040234513 Composition and method for reducing blood glucose
11/25/2004	US20040234512 Method for treating thrombopoiesis and anemia; cytosine phosphate diester guanine; controlling remodeling of immunology system
11/25/2004	US20040234497 complexing hyaluronic acidand cell surface receptor overexpression on cancer cell surfaces
11/25/2004	US20040234495 Antitumor agents and process for producing the same
11/25/2004	US20040234494 biocompatible , biodegradation ; increase drug concentration; stability
11/25/2004	US20040234493 Quaternary polyamidoamines, the production thereof, corresponding agents and the use thereof
11/25/2004	US20040234490 mixture containing phenolsulfonic acid with sulfosalicylic acid, citric acid
11/25/2004	US20040234480 Use of oligomeric proanthrocyanidins
11/25/2004	US20040234472 Micellar drug delivery systems for hydrophobic drugs
11/25/2004	US20040234464 Photoprotective cosmetic compositions comprising para-aminobenzalmalonate-substituted s-triazine compounds
11/25/2004	US20040234459 exterior shell enclosing a cavity containing liquid drug
11/25/2004	US20040234457 in situ administering into respiratory system a mixture of organic acid and metal compound
11/25/2004	US20040234450 Compositions, methods, apparatuses, and systems for singlet oxygen delivery
11/25/2004	US20040233760 Magnetic random access memory array with coupled soft adjacent magnetic layer
11/25/2004	US20040232089 Adding menadione nicotinamide bisulphite, menadione dimethylpyrimidinole bisulphite, menadione nicotinic acid bisulphite, menadione adenine bisulphite, menadione triptophane bisulphite, menadione histidine bisulphite, menadione para-aminobenzoic acid bisulphite to the water for elimination or prevention
11/25/2004	US20040231666 Adsorbents and uses thereof
11/25/2004	DE4307422B4 Verfahren zur Herstellung von Clavulansäuresalzen Process for the preparation of salts of clavulanic acid
11/25/2004	DE20221047U1 Serial battery charger including charging section, which includes at least first and second parallel- connected branches has one-way electronic device of very low-impedance when current flows from charging section into battery terminals
11/25/2004	DE20220982U1 Transdermal patch, useful for administering fentanyl or its analog through the skin, comprises a backing layer on which a reservoir containing a single phase polymeric composition is disposed
11/25/2004	DE10320983A1 Synergistic cholesterol lowering composition, useful as medicament or food or feed additive, comprising dietary fiber component and ahypocholesterolemic agent, e.g. statin
11/25/2004	DE10320084A1 Formulation useful in the treatment of neurogenic and idiopathic bladder hyperactivity comprises phenoxyacetic acid derivative
11/25/2004	DE10318896A1 8beta-Vinyl-11beta-(omega-substituierte)alkyl-estra-1,3,5(10)-triene 8beta-vinyl-11beta- (omega-substituted) alkyl-estra-1,3,5 (10) -trienes
11/25/2004	DE10308351A1 1,3-substituierte Cycloalkylderivate mit sauren, meist heterocyclischen Gruppen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel 1,3-substituted cycloalkyl derivatives having acidic, mostly heterocyclic groups, processes for their preparation and their use as medicaments
11/25/2004	CA2625837A1 Method for enhancing cognition using ziprasidone
11/25/2004	CA2617420A1 Therapeutic combinations of atypical antipsychotics with gaba modulators, anticonvulsants or benzodiazapines
11/25/2004	CA2566874A1 Targeted delivery of anti-viral compounds through hemoglobin bioconjugation
11/25/2004	CA2566192A1 Method for increasing breast meat yield in poultry
11/25/2004	CA2528220A1 Indazole-derivatives as factor xa inhibitors
11/25/2004	CA2527756A1 Immunostimulating agents
11/25/2004	CA2526458A1 Further therapeutic use of zolpidem
11/25/2004	CA2526084A1 Azaindole-derivatives as factor xa inhibitors
11/25/2004	CA2526066A1 New indole derivatives as factor xa inhibitors
11/25/2004	CA2526065A1 Benzimidazole-derivatives as factor xa inhibitors
11/25/2004	CA2526025A1 Preventive and/or remedy for diseases accompanied by tissue destruction
11/25/2004	CA2525929A1 Methods of modulating metastasis and skeletal related events resulting from metastases
11/25/2004	CA2525907A1 Rapamycin carbohydrate derivatives
11/25/2004	CA2525868A1 Anxiety treatments with ziprasidone
11/25/2004	CA2525866A1 Treatment of psychotic and depressive disorders
11/25/2004	CA2525860A1 Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof
11/25/2004	CA2525858A1 Diarylmethylidene piperidine derivatives and their use as delta opioid receptor agonists
11/25/2004	CA2525849A1 4-arylsulphonylpiperidine derivatives for antagonism of the 5-ht2a receptor
11/25/2004	CA2525684A1 Sulfamate benzothiophene derivatives as steroid sulfatase inhibitors
11/25/2004	CA2525665A1 Pharmaceutical composition comprising valsartan
11/25/2004	CA2525651A1 Estratriene derivatives
11/25/2004	CA2525539A1 Treatment kit to assist in antibiotic therapy in intracellular infectious diseases
11/25/2004	CA2525526A1 Combination of the analeptic modafinil and an antidepressant for the treatment of depression
11/25/2004	CA2525465A1 Topical composition for transdermal administration
11/25/2004	CA2525459A1 Novel 14 and 15 membered-ring compounds
11/25/2004	CA2525457A1 Novel 14 and 15 membered ring compounds
11/25/2004	CA2525455A1 Novel 14 and 15 membered-ring compounds
11/25/2004	CA2525452A1 Novel 14 and 15 membered-ring compounds
11/25/2004	CA2525449A1 Macrolides substituded at the 4"-position
11/25/2004	CA2525442A1 Cyanofluoropyrrolidine derivatives
11/25/2004	CA2525438A1 Glyoxalase inhibitors
11/25/2004	CA2525367A1 Use of citrate lyase inhibitors and tricarboxylate transporter inhibitors in the treatment of cancer
11/25/2004	CA2525366A1 Therapeutic combinations of atypical antipsychotics with gaba modulators, anticonvulsants or benzodiazapines
11/25/2004	CA2525326A1 Treatment of bipolar disorders and associated symptoms
11/25/2004	CA2525323A1 Method for enhancing cognition using ziprasidone
11/25/2004	CA2525318A1 Bicalutamide forms, compositions, and processes thereof
11/25/2004	CA2525316A1 Pioglitazone salts, such as pioglitazone sulfate, and pharmaceutical compositions and processes using the same
11/25/2004	CA2525143A1 New 3-decladinosyl 9a-n-carbamoyl and 9a-n-thiocarbamoyl derivatives of 9-deoxo-9-dihydro-9a-aza-9a-homoerythromycin a
11/25/2004	CA2525124A1 Bridged n-arylsulfonylpiperidines as gamma-secretase inhibitors
11/25/2004	CA2525111A1 Drug formulations having reduced abuse potential
11/25/2004	CA2525104A1 Polymorphs of cabergoline
11/25/2004	CA2525099A1 Cytotoxic indeno and isoindoloisoquinolones
11/25/2004	CA2525006A1 `(2-hydroxy-2-(4-hydroxy-3-hydoxymethylphenyl)-ethylamino)-propyl!phenyl derivatives as beta2 agonists
11/25/2004	CA2524958A1 Isoquinoline derivatives and their use as gfat inhibitors
11/25/2004	CA2524883A1 Potassium-chloride cotransporter kcc2 modulation for treatment of pain
11/25/2004	CA2524847A1 Pharmaceutical compositions of antithrombin iii for the treatment of retroviral diseases
11/25/2004	CA2524827A1 Controlled release formulation of erythromycin derivatives
11/25/2004	CA2524780A1 Compounds for treatment of inflammation, diabetes and related disorders
11/25/2004	CA2524470A1 Preparation and use of aryl alkyl acid derivatives for the treatment of obesity
11/25/2004	CA2524436A1 Benzimidazoles, compositions containing such compounds and methods of use
11/25/2004	CA2524434A1 Benzyl sulfonamide derivatives as androgen receptor antagonists
11/25/2004	CA2524290A1 Mold inhibitor integrated within a matrix and method of making same
11/25/2004	CA2524228A1 Method of preparing a formulation containing a microdosed active principle
11/25/2004	CA2524097A1 Alcohol-free transdermal analgesic composition
11/25/2004	CA2524036A1 Treatment of neurodegenerative conditions
11/25/2004	CA2523978A1 Crystal of benzimidazole derivative and process for producing the same
11/25/2004	CA2523940A1 Method and kit for regulation of microvascular tone
11/25/2004	CA2523785A1 Small interfering rna libraries and methods of synthesis and use
11/25/2004	CA2523746A1 Method of treating atrial fibrillation or atrial flutter
11/25/2004	CA2523045A1 Anti-inflammatory phosphonate compounds
11/25/2004	CA2523000A1 Oral care methods and products
11/25/2004	CA2522765A1 Dietary supplement and method for the treatment and prevention of digestive tract ulcers in equines and other animals
11/25/2004	CA2522690A1 Inhibition of drug binding to serum albumin
11/25/2004	CA2522404A1 One or several enzyme-containing compounds, dietetic food products and drugs produced from said compounds and the use therefor for medical purposes
11/24/2004	EP1480042A2 Method of screening compounds interacting with proteins of the p53 family
11/24/2004	EP1479711A1 Multidrop tree branching functional polyethylene glycol, the preparation method and the use of it
11/24/2004	EP1479682A1 Immunosuppressive effects of pteridine derivatives
11/24/2004	EP1479681A1 IMIDAZO(1,2-a)PYRIDINE DERIVATIVE
11/24/2004	EP1479676A1 Benzimidazole-derivatives as factor xa inhibitors
11/24/2004	EP1479675A1 Indazole-derivatives as factor Xa inhibitors
11/24/2004	EP1479671A1 Pyrimidinone compounds
11/24/2004	EP1479670A1 Novel fused ring indazole compounds

1 ... 4881 4882 4883 4884 4885 4886 4887 4888 4889 4890 4891 4892 4893 4894 4895 4896 4897 4898 4899 4900 4901 ... 7860